OrthoPediatricsKIDS
KIDS
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
657% more call options, than puts
Call options by funds: $53K | Put options by funds: $7K
0.6% more ownership
Funds ownership: 67.53% [Q3] → 68.13% (+0.6%) [Q4]
10% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 39
13% less funds holding
Funds holding: 124 [Q3] → 108 (-16) [Q4]
14% less capital invested
Capital invested by funds: $443M [Q3] → $383M (-$60.7M) [Q4]
53% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 30
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
28%
upside
Avg. target
$41
65%
upside
High target
$50
100%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Citizens Capital Markets David Turkaly 31% 1-year accuracy 8 / 26 met price target | 100%upside $50 | Market Outperform Reiterated | 21 Mar 2025 |
Stifel Rick Wise 43% 1-year accuracy 15 / 35 met price target | 28%upside $32 | Buy Maintained | 5 Mar 2025 |
Needham Mike Matson 40% 1-year accuracy 50 / 124 met price target | 68%upside $42 | Buy Reiterated | 5 Mar 2025 |
Financial journalist opinion
Based on 7 articles about KIDS published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
OrthoPediatrics Corp. to Participate in the 24th Annual Needham Virtual Healthcare Conference
WARSAW, Ind., March 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

Neutral
GlobeNewsWire
1 week ago
OrthoPediatrics Corp. Named One the 2025 Best Places to Work in Indiana
WARSAW, Ind., March 24, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was selected as one of the 2025 Best Places to Work in Indiana. This is the 9th time the Company has been recognized by the annual program created by the Indiana Chamber of Commerce.

Neutral
GlobeNewsWire
2 weeks ago
OrthoPediatrics Corp. Joins Crossroads Pediatric Device Consortium to Advance Pediatric Medical Device Innovation
WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads Pediatric Device Consortium (CPDC). This collaboration aligns with the Company's cause of improving the lives of children by supporting the development and commercialization of innovative pediatric medical devices.

Neutral
Seeking Alpha
3 weeks ago
OrthoPediatrics Corp. (KIDS) Q4 2024 Earnings Call Transcript
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group, IR David Bailey - President and CEO Fred Hite - Chief Operating and Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Rick Wise - Stifel Matthew O'Brien - Piper Sandler Joseph Conway - Needham & Company Operator Hello. And welcome to OrthoPediatrics Corporation's Fourth Quarter and Full Year 2024 Earnings Conference Call.

Neutral
Zacks Investment Research
3 weeks ago
Compared to Estimates, OrthoPediatrics (KIDS) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Negative
Zacks Investment Research
3 weeks ago
OrthoPediatrics (KIDS) Reports Q4 Loss, Misses Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago.

Neutral
GlobeNewsWire
3 weeks ago
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2024.

Neutral
GlobeNewsWire
1 month ago
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
WARSAW, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, March 4, 2025 at 4:30 p.m. ET to discuss the results.

Neutral
GlobeNewsWire
2 months ago
OrthoPediatrics Corp. Announces Distribution Agreement with Thrive Orthopedics LLC
WARSAW, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company gained distribution rights to bring additional bracing solutions to the US market through its OrthoPediatrics Specialty Bracing (OPSB) division.

Neutral
GlobeNewsWire
2 months ago
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance
Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-YearInitiates guidance for record adjusted EBITDA in 2025

Charts implemented using Lightweight Charts™